Sagimet Biosciences Inc. Marketable Securities (Current)
Sagimet Biosciences Inc. (SGMT) had Marketable Securities (Current) of $74.23 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-11
- 2026-06-30: Marketable Securities, Current $74.23M.
- 2026-03-31: Marketable Securities, Current $67.91M.
- 2025-12-31: Marketable Securities, Current $78.10M.
- 2025-09-30: Marketable Securities, Current $84.20M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $74.23M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $67.91M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $78.10M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $84.20M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $83.08M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $79.85M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $75.41M 10-K · filed 2026-03-11 |
| 2024-09-30 | $75.47M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $70.41M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $16.93M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $19.76M 10-K · filed 2025-03-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-21 |
| 2022-12-31 | $32.19M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |